Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status.

    J Psychiatr Pract 2017 May;23(3):191-199
    FRYML, WILLIAMS, PELIC, FOX, SAHLEM, ROBERT, and SHORT: Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC REVUELTA: Department of Neurology and Neurosciences, Medical University of South Carolina, Charleston, SC.
    Amantadine, which was originally developed as an antiviral medication, functions as a dopamine agonist in the central nervous system and consequently is utilized in the treatment of Parkinson disease, drug-induced extrapyramidal reactions, and neuroleptic malignant syndrome. For reasons that are not entirely understood, abrupt changes in amantadine dosage can produce a severe withdrawal syndrome. Existing medical literature describes case reports of amantadine withdrawal leading to delirium, which at times has progressed to neuroleptic malignant syndrome. Amantadine withdrawal may be under-recognized by mental health clinicians, which has the potential to lead to protracted hospital courses and suboptimal outcomes. The goal of this case series is to highlight the role of amantadine withdrawal in the cases of 3 medically complex patients with altered mental status. In the first case, the cognitive side effects of electroconvulsive therapy masked acute amantadine withdrawal in a 64-year-old man with Parkinson disease. In the second case, a 75-year-old depressed patient developed a catatonic delirium when amantadine was discontinued. Finally, a refractory case of neuroleptic malignant syndrome in a 57-year-old patient with schizoaffective disorder rapidly resolved with the reintroduction of outpatient amantadine. These cases highlight several learning objectives regarding amantadine withdrawal syndrome: First, it may be concealed by co-occurring causes of delirium in medically complex patients. Second, its symptoms are likely to be related to a cortical and limbic dopamine shortage, which may be reversed with electroconvulsive therapy or reintroduction of amantadine. Third, its clinical presentation may occur on a spectrum and may include features suggestive of delirium, catatonia, or neuroleptic malignant syndrome.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
    Source Status
    http://dx.doi.org/10.1097/PRA.0000000000000237DOI ListingPossible

    Similar Publications

    Neuroleptic-induced catatonia after abrupt withdrawal of amantadine during neuroleptic therapy.
    Pharmacotherapy 1986 Jul-Aug;6(4):193-5
    Catatonic reactions to high-potency neuroleptic drugs have been described in the literature. Our patient developed neuroleptic-induced catatonia (NIC) after abrupt withdrawal of amantadine, a dopaminergic agent that has been implicated in neuroleptic malignant syndrome (NMS) on its discontinuation. This case report adds support to the hypothesis that NIC and NMS are 2 syndromes on a continuum of dopamine blockade, each of which may be treated with or uncovered by amantadine therapy. Read More
    A Case Report of Severe Delirium after Amantadine Withdrawal.
    Case Rep Neurol 2017 Jan-Apr;9(1):44-48. Epub 2017 Mar 20.
    bDepartment of Neurology, University Hospital Erlangen, FAU, Erlangen, Germany.
    Amantadine is frequently used in addition to dopaminergic substances like dopamine agonists or L-Dopa in advanced Parkinson disease (PD). However, adverse effects like hallucinations limit its use. PD patients developing severe psychotic symptoms upon treatment with either dopaminergic substances and/or amantadine need to stop intake of any psychotropic substance. Read More
    [Acute catatonic syndrome after neuroleptic malignant syndrome].
    Encephale 2005 Nov-Dec;31(6 Pt 1):705-9
    Centre Psychiatrique Universitaire Ibn Rochd, Maroc.
    We report the case of a young woman who deve-loped catatonic syndrome a few days after neuroleptic mali-gnant syndrome (NMS), arising the problem of the chronology of both affections. A 20-year old woman with an history of bipolar disorder, experienced an acute manic syndrome that made hospitalization necessary. Fourteen days after loxa-pine prescription, the patient developed a NMS (DSM IV criteria) dyskinesia, dysphagia, fever and alteration of cons-ciousness. Read More
    Neuroleptic malignant syndrome: a case responding to electroconvulsive therapy plus bupropion.
    Clin Pract 2018 Jan 26;8(1):1044. Epub 2018 Jan 26.
    Department of Psychiatry, Vic University Hospital, Vic, Spain.
    Neuroleptic malignant syndrome (NMS) is a severe motor syndrome occurring as a consequence of neuroleptic treatment. We present a case of a 67-year-old Caucasian woman with a history of a major depressive disorder with psychotic features. During her third hospital admission, symptoms of autonomic instability, hyperpyrexia, severe extrapyramidal side effects, and delirium appeared, suggesting NMS due to concomitant treatment with risperidone and quetiapine, among other drugs. Read More